EXHIBIT A

EXHIBIT A: PENDING CLAIMS

What is claimed is:

- 1. (Original) A method of treating or prophylaxis of a disorder ameliorated by the inhibition of serotonin reuptake at 5-HT₂ receptors and/or the inhibition of dopamine reuptake at dopamine D₂ receptors in a patient which comprises administering to a patient in need of such treatment or prophylaxis a therapeutically effective amount of a ziprasidone metabolite, or a pharmaceutically acceptable salt, solvate, hydrate, or clathrate thereof.
- 2. (Currently Amended) The method of claim 1 wherein the disorder is selected from the group consisting of a neuroleptic disorders, a migraines, acute intermittent porphyria, intractable hiccups, Parkinson's disease and or epilepsy.
- 3. (Original) A method of treating or prophylaxis of a neuroleptic disorder in a patient which comprises administering to a patient in need of such treatment or prophylaxis a therapeutically effective amount of a ziprasidone metabolite, or a pharmaceutically acceptable salt, solvate, hydrate, or clathrate thereof.
 - 4. (Original) The method of claim 1 or 3 wherein the patient is a human.
- 5. (Previously Amended) The method of claim 1 wherein the ziprasidone metabolite is ziprasidone sulfoxide or ziprasidone sulfone.
- 6. (Currently Amended) The method of claim 3 wherein the neuroleptic disorder is selected from the group consisting of psychosis, an affective disorders, and or anxiety.
- 7. (Currently Amended) The method of claim 6 wherein the psychosis is selected from the group consisting of schizophrenia, schizo-affective psychosis, hallucinations, paranoia, affective psychosis, alcoholic psychoses, arteriosclerotic psychosis, amnestic psychosis, bipolar psychosis, Cheyne-Stokes psychosis, climacteric psychosis, depressive psychosis, drug psychosis, dysmnesic psychosis, hysterical psychosis,

infection-exhaustion psychosis, Korsakoff's psychosis, postinfectious psychosis, postpartum psychosis, posttraumatic psychosis, senile psychosis, situational psychosis, toxic psychosis, traumatic psychosis, and or Windigo psychosis.

3.1

3 ,

- 8. (Currently Amended) The method of claim 6 wherein the affective disorder is selected from the group consisting of depression, attention deficit disorder, attention deficit disorder with hyperactivity, bipolar conditions and or manic conditions.
- 9. (Currently Amended) The method of claim 6 wherein the anxiety is selected from the group consisting of anxiety attacks, free-floating anxiety, noetic anxiety, separation anxiety, and or situation anxiety.
- 10. (Original) The method of claim 1 or 3 wherein the ziprasidone metabolite is administered parenterally, transdermally, mucosally, nasally, buccally, sublingually, or orally.
- 11. (Original) The method of claim 10 wherein the ziprasidone metabolite is administered orally.
- 12. (Original) The method of claim 11 wherein the ziprasidone metabolite administered orally in a tablet or capsule form.
- 13. (Original) The method of claim 1 or 3 wherein the therapeutically effective amount of ziprasidone metabolite is between about 1 mg and about 1000 mg per day.
- 14. (Original) The method of claim 13 wherein the therapeutically effective amount of ziprasidone metabolite is between about 5 mg to about 500 mg per day.
- 15. (Original) The method of claim 14 wherein the therapeutically effective amount of ziprasidone metabolite is between about 10 mg to about 200 mg per day.
- 50. (Previously Added) A method of treating or prophylaxis of a neuroleptic disorder in a patient which comprises administering to a patient in need of such

treatment or prophylaxis a therapeutically effective amount of ziprasidone sulfoxide, or a pharmaceutically acceptable salt, solvate, hydrate, or clathrate thereof.

- 51. (Previously Added) The method of claim 50 wherein the neuroleptic disorder is psychosis, an affective disorder, or anxiety.
- 52. (Previously Added) A method of treating or prophylaxis of a neuroleptic disorder in a patient which comprises administering to a patient in need of such treatment or prophylaxis a therapeutically effective amount of ziprasidone sulfone, or a pharmaceutically acceptable salt, solvate, hydrate, or clathrate thereof.
- 53. (Previously Added) The method of claim 52 wherein the neuroleptic disorder is psychosis, an affective disorder, or anxiety.

EXHIBIT A: PENDING CLAIMS

What is claimed is:

- 1. (Original) A method of treating or prophylaxis of a disorder ameliorated by the inhibition of serotonin reuptake at 5-HT₂ receptors and/or the inhibition of dopamine reuptake at dopamine D₂ receptors in a patient which comprises administering to a patient in need of such treatment or prophylaxis a therapeutically effective amount of a ziprasidone metabolite, or a pharmaceutically acceptable salt, solvate, hydrate, or clathrate thereof.
- 2. (Currently Amended) The method of claim 1 wherein the disorder is selected from the group consisting of a neuroleptic disorder, a migraines, acute intermittent porphyria, intractable hiccups, Parkinson's disease and or epilepsy.
- 3. (Original) A method of treating or prophylaxis of a neuroleptic disorder in a patient which comprises administering to a patient in need of such treatment or prophylaxis a therapeutically effective amount of a ziprasidone metabolite, or a pharmaceutically acceptable salt, solvate, hydrate, or clathrate thereof.
 - 4. (Original) The method of claim 1 or 3 wherein the patient is a human.
- 5. (Previously Amended) The method of claim 1 wherein the ziprasidone metabolite is ziprasidone sulfoxide or ziprasidone sulfone.
- 6. (Currently Amended) The method of claim 3 wherein the neuroleptic disorder is selected-from the group consisting of psychosis, an affective disorders, and or anxiety.
- 7. (Currently Amended) The method of claim 6 wherein the psychosis is selected from the group consisting of schizophrenia, schizo-affective psychosis, hallucinations, paranoia, affective psychosis, alcoholic psychoses, arteriosclerotic psychosis, amnestic psychosis, bipolar psychosis, Cheyne-Stokes psychosis, climacteric psychosis, depressive psychosis, drug psychosis, dysmnesic psychosis, hysterical psychosis,